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ABSTRACT: Inhibitor design incorporating features of the reaction coordinate and transition=state structure has emerged as a 
powerful approach for the development of enzyme inhibitors. Such inhibitors find use as mechanistic probes, chemical biology 
tools and therapeutics. Endo=α=1,2=mannosidases and endo=α=1,2=mannanases, members of glycoside hydrolase family 99 (GH99), 
are interesting targets for inhibitor development as they play key roles in N=glycan maturation and microbiotal yeast mannan degra=
dation, respectively. These enzymes are proposed to act via an 1,2=anhydrosugar 'epoxide' mechanism that proceeds through a pro=
posed unusual conformational itinerary. Here, we explore how charge and shape contribute to binding of diverse inhibitors of these 
enzymes. We report the synthesis of neutral dideoxy, glucal and cyclohexenyl disaccharide inhibitors, their binding to GH99 endo=
α=1,2=mannanases, and their structural analysis by X=ray crystallography. Quantum mechanical calculations of the free energy land=
scapes reveal how the neutral inhibitors provide shape but not charge mimicry of the proposed intermediate and transition state 
structures. Building upon the knowledge of shape and charge contributions to inhibition of family GH99 enzymes, we design and 
synthesize α=Man=1,3=noeuromycin, which is revealed to be the most potent inhibitor (KD 13 nM for Bacteroides xylanisolvens 
GH99 enzyme) of these enzymes yet reported. This work reveals how shape and charge mimicry of transition state features can 
enable the rational design of potent inhibitors. 
	 !"#!	
Over 500,000 gene sequences have been discovered en=
coding glycoside hydrolases that are grouped into more than 
130 families according to the Carbohydrate Active enZyme 
classification (CAZy: www.cazy.org).1 Glycoside hydrolases 
of family 99 possess two distinct activities: endo=α=1,2=
mannosidase and endo=α=1,2=mannanase. Endo=α=1,2=
mannosidases are eukaryotic proteins involved in N=linked 
glycan maturation, folding, and quality control2=5 and are of 
clinical significance as they provide a means for viruses and 
cancer to evade the effect of exo=glucosidase inhibitors.5,6 En&
do=α=1,2=mannanases are produced by Bacteroides spp., bacte=
rial residents of the gut microbiota.7 They facilitate the degra=
dation of dietary yeast mannan consumed in bread and fer=
mented foods, facilitating the breakdown of these complex 
carbohydrates, with beneficial effects on the gastrointestinal 
tract and, possibly, mitigating the symptoms of Crohn's dis=
ease.8 Given the importance of family GH99 enzymes in N=
linked glycan maturation and carbohydrate processing by the 
microbiota, the development of inhibitors has been of particu=
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lar importance to allow assessment and manipulation of their 
roles in these complex processes. In this work we investigate 
several mechanism=inspired inhibitor design concepts for fam=
ily GH99 endo=α=1,2=mannanases BtGH99 and BxGH99, from 
the gut microbiota constituents Bacteroides thetaiotaomicron 
and Bacteroides xylanisolvens, respectively, that cast light on 
the importance of structural mimicry of charge and shape of 
species along the reaction coordinate in achieving potent inhi=
bition of this enzyme family.  
Glycosidases that cleave their substrates with retention of 
anomeric configuration typically operate through a two=step 
mechanism that proceeds via a covalent glycosyl enzyme in=
termediate. Such enzymes utilize enzymatic amino acid resi=
dues that in the first step act as general acid and nucleophile to 
assist in departure of the anomeric substituent while simulta=
neously substituting the anomeric group; in the second step the 
first carboxylate acts as a general base to deprotonate a nucle=
ophilic water molecule that hydrolyzes the covalent glycosyl 
enzyme intermediate (Figure 1A).9,10  Important exceptions 
include a range of β=hexosaminidases that perform catalysis 
through mechanisms involving neighboring group participa=
tion by the 2=acetamido group of the substrate (Figure 1B).11 
These enzymes also operate through a two=step mechanism: in 
the first step an amino acid residue acts as a general acid to 
assist in departure of the leaving group while the 2=acetamido 
group performs a nucleophilic attack on the anomeric center, 
forming a bicyclic oxazoline/oxazolinium ion intermediate. In 
the second step the same amino acid residue acts as a general 
base, assisting nucleophilic attack by a water molecule that 
opens the oxazolinium ion ring, reforming the 2=acetamido 
group and completing the hydrolysis reaction.  
Figure 1. A) Mechanism for a canonical retaining α=
glycosidase that proceeds through a covalent glycosyl=enzyme 
intermediate. B) Mechanism for a retaining β=hexosaminidase 
involving neighboring group participation by the 2=acetamido 
group, via an oxazolinium ion intermediate. C) Proposed 
mechanism for family GH99 α=mannosidases involving 
neighboring group participation by the 2=OH group, via a 1,2=
anhydro sugar (epoxide). Numbering is for BxGH99. 
Family GH99 enzymes cleave glycosides with an overall 
retention of anomeric configuration.12 X=ray structures are 
now available for GH99 enzymes in complex with a variety of 
ligands based on sugar=shaped heterocycles.7,8,12 However, in 
X=ray structures of B. xylanisolvens BxGH99 with various 
substrate=mimicking ligands it was not possible to identify an 
appropriately positioned enzymatic nucleophile within the 
typical <3 Å distance from the reactive anomeric center, lead=
ing to the proposal of a non=classical mechanism.12 In particu=
lar, in structures of GlcIFG (2) and ManIFG (3) with BxGH99, 
there were no close contacts with a likely candidate enzymatic 
nucleophile,7,12 at odds with the usual observation of a carbox=
ylate situated typically 2.6–2.7 Å away in classical retaining 
glycosidases. Moreover, in complexes of GlcDMJ (1) with 
BxGH99 a conserved carboxyl residue (E333; numbering re=
fers to BxGH99) was located 2.7 Å from the 2=OH group;12 
similar observations extend to the binding of a substrate (α=
Man=1,3=α=ManMU) to the carboxamide mutant BxGH99 
E333Q.7 Collectively these data supported the proposal of a 
two=step reaction involving in the first step the formation of a 
bicyclic 1,2=anhydro sugar intermediate, through E333 acting 
as a general base residue to deprotonate the 2=OH and facilitat=
ing a nucleophilic substitution at C1 coincident with departure 
of the leaving group, assisted by E336 acting as general acid, 
(Figure 1C).12 In the second step of this proposed mechanism, 
E333 acts as a general acid, assisting ring opening of the epox=
ide, while E336 acts as a general base, promoting nucleophilic 
attack by a water molecule. While such a mechanism lacks 
precedent in enzymes, there is strong evidence that the base=
catalyzed solvolysis of 4=nitrophenyl α=D=mannoside and α=
mannosyl fluoride proceed through similar neighboring group 
participation mechanisms.13=16 The most stable conformation 
of 1,2=anhydro=β=D=mannose is a 4H5 half=chair; applying the 
principle of least nuclear motion a 4C1 → 
4
E
‡ → 4H5 confor=
mational itinerary has been proposed for the first step of the 
family GH99 reaction coordinate.17 
Intensive efforts have been invested in the rational devel=
opment of glycosidase inhibitors, and many fundamental prin=
ciples have been articulated inspired by our deep mechanistic 
understanding of this class of enzyme. Based on pioneering 
insights from Pauling18 and Wolfenden,19 it is recognized that 
a common principle underpinning catalysis is the selective 
affinity of an enzyme for a reaction transition state, relative to 
the ground state. Accordingly, inhibitor design by transition 
state mimicry, which can take advantage of the high transition 
state affinity of a glycosidase, has proven a useful guiding 
strategy.20 While it is widely appreciated that perfect transition 
state mimics are chemically unstable and thus unattainable, a 
general design principle is to develop analogues incorporating 
features that mimic the shape and charge of the transition 
state.20 Three basic features have been highlighted for consid=
eration in the development of effective glycosidase inhibitors: 
configuration, conformation and charge.21 Configuration is the 
simplest to address and not surprisingly it is usually found that 
glycosidases are normally best targeted by inhibitors with ste=
reochemistry matching that of the substrate. In the case of 
BxGH99, an enzyme that has the ability to cleave both α=Glc=
1,3=α=Man=OR and α=Man=1,3=α=Man=OR configured sub=
strates (with a preference for the latter)7 optimal inhibition is 
achieved by inhibitors matching the preferred substrate con=
figuration. Glycosidases typically operate through transition 
states with substantial oxocarbenium ion character, and partial 
double bond development between O5 and C1, leading to a 
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flattened conformation at the transition state. Consequently, 
mimicry of the flattened conformation expected at the transi=
tion state has proven a second effective strategy, with inhibi=
tors bearing sp2=hybridized atoms at the anomeric or endocy=
clic oxygen positions, such as glyconolactones and =lactams, 
identified as fairly broad spectrum glycosidase inhibitors. Fi=
nally, partial charge development at C1 and the endocyclic 
oxygen at the transition state can be mimicked by the proto=
nated forms of nitrogen=containing heterocycles, exemplified 
by deoxymannojirimycin (DMJ) with a nitrogen in place of 
the endocyclic oxygen, and isofagomine with a nitrogen in 
place of C1.  
Motivated by the unusual mechanism proposed for family 
GH99 enzymes and the complexity of their biochemical roles, 
our understanding of which should benefit from the develop=
ment of potent inhibitors, we undertook a study of several 
inhibitor designs inspired by the concepts of charge and shape 
mimicry. GlcDMJ (1), an inhibitor reported by Spiro and 
coworkers,22 was the first effective inhibitor of mammalian 
endo=α=1,2=mannosidase,6 and was subsequently shown to 
bind to and inhibit BxGH99 and BtGH99 (Table 1).12 More 
potent inhibition was achieved by GlcIFG (2),12 which also 
proved to be a more effective inhibitor than GlcDMJ of mam=
malian endo=α=1,2=mannosidase in cell=based studies,23 
demonstrating that varying the position of charge can provide 
improvements in potency. Further, upon identification of the 
Bacteroides spp. enzymes as preferential endo=α=1,2=
mannanases,7,8 we were able to configurationally match the 
substrate and develop the inhibitor ManIFG (3), the most po=
tent inhibitor yet reported for any GH99 enzyme.7 However, 
ManIFG and GlcIFG lack the 2=OH group of the substrate and 
thus cannot benefit from specific interactions with the putative 
acid/base E333. Separately, Spiro and coworkers reported that 
two other neutral compounds were almost as effective as 
GlcDMJ in the inhibition of mammalian endo=α=1,2=
mannosidase, namely GlcddMan (4) and GlcGlucal (6).6,24 We 
were intrigued by these observations and sought to investigate 
whether the equivalent configurationally=matched species, 
ManddMan (5) and ManGlucal (7), and the related cyclohex=
ene derivative (8) were inhibitors of bacterial GH99 enzymes 
and to understand how they bind to the enzyme. 
 
 
 
 
 
Table 1. Dissociation constants for GH99 %mannanase 
inhibitors 
Compound D values (M) Method 
 GH99 	GH99  
1 (GlcDMJ) 24 NDa ITC12 
2 (GlcIFG) 0.63 NDa ITC12 
3 (ManIFG) 0.14 0.27 ITC6 
5 (ManddMan) 53 ± 5 221 ± 11 NMR 
7 (ManGlucal) 15 ± 1.9 111 ± 11 NMR 
8 (GlcChex) no binding no binding NMR/ITC 
9 (ManNOE) 0.03 ± 0.01 0.013 ± 0.002 ITC 
a ND, not determined. 
	 $%#&%	'"	"%#%%!	
%	
	(	((		()	
ManddMan (5) and ManGlucal (7) were prepared from α=
1,3=mannobiose (10) (Scheme 1). Acetylation, followed by 
bromination afforded mannobiosyl bromide (12), which was 
converted to the protected glucal (13) using Zn in MeOH. 
Zemplén transesterification afforded ManGlucal (7). Alterna=
tively, reduction of 13 using H2/Pd=C, followed by Zemplén 
transesterification afforded ManddMan (5). The preparation of 
GlcChex (8) will be described elsewhere. 
 
Scheme 1. Synthesis of ManddMan (5) and ManGlucal (7). 
 
*		+"			
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Dissociation constants for the binding of com=
pounds 5 and 7 to BtGH99 and BxGH99 were determined by 
NMR spectroscopy (Figure S1). The 2D NMR SOFAST=
HMQC spectra of 15N=labelled enzymes determined in the 
presence or absence of a saturating amount of the ligands re=
vealed several H=N peaks that displayed significant chemical 
shift perturbations. For instance, new signals for an arginine 
residue (assigned as R295 in BxGH99 and R291 in BtGH99 on 
the basis of analysis of inter=residue nOes from the 3D=HSQC=
NOESY spectra; see annotation to Figure 4A) appeared during 
the titration experiments, which were in slow exchange with 
the initial ones in the chemical shift time scale (Figure 2). 
Therefore, since the relative intensities of these signals are 
proportional to the populations of the bound and unbound 
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forms (see Experimental and SI), the dissociation con=
stants (KD) were readily calculated. The binding constants are 
shown in Table 1. No evidence for binding of GlcChex could 
be obtained by either NMR or ITC. 
 
Figure 2. Excerpt of the side chain HN ε=arginine region in 
the 2D SOFAST=HMQC NMR spectra of 15N=
labelled BtGH99 in the absence (blue) or presence of an ex=
cess of (top) ManGlucal (7; red) or (bottom)ManddMan (5; 
green) . The arrow highlights the chemical shift perturbation 
observed for the HN=ε signal corresponding to R295.  
In order to analyze the mode of binding of the conforma=
tionally=restricted compounds, 3=D structures of complexes of 
BxGH99 with 7 and 8 were determined by X=ray crystallog=
raphy at near atomic (approx. 1.0 Å) resolutions (Table 2, 
Figure 3A,B). ManGlucal 7 (KD 111 M) binds to BxGH99 in 
the –2 and –1 subsites, with the –1 glucal ring intact in a 4H5 
conformation. For reasons most likely related to its poor af=
finity for the enzyme, we were unable to obtain a complex of 
GlcChex with wildtype enzyme, but were serendipitously suc=
cessful in obtaining a complex with the catalytically inactive 
BxGH99 E333Q mutant. In this complex GlcChex 8 also 
bound in the –2/–1 subsite with the cyclohexene ring in a 4H5 
conformation (Figure 3B). Relative to ManGlucal, GlcChex 
suffers both by replacement of the endocyclic oxygen with 
methylene and by the presence of a non=reducing=end glucosyl 
moiety, the latter of which is known to reduce binding to the 
Bacteroides spp. enzymes by 4–10 fold.7 Owing to the un=
measurable binding of GlcChex, the synthesis of the mannose 
analogue was not pursued. The lack of oxygen atoms within 
the GlcChex ring means it cannot form hydrogen bonds with 
active site residues Y252, E333 or E336. MS experiments 
indicated that the compound is not affected by the enzyme or 
its variants so the reason for binding to only the inactive vari=
ant is unclear. 
Glycals are often effective inhibitors of classical retaining 
glycosidases. Inhibition is typically found to be time=
dependent, owing to a chemical reaction in which the nucleo=
phile protonates the enol ether of the glycal, and forms a 2=
deoxy=glycosyl enzyme.25,26 This mode of reactivity has been 
exploited to allow the identification of the catalytic nucleo=
phile by peptide sequencing,25 and the 2=deoxyglycosyl=
enzymes are sufficiently stable to be studied by X=ray crystal=
lography.27 To date, only two classes of retaining glycosidases  
 
 
Figure 3. Stereoview of active site of B. xylanisolvens family GH99 enzyme complexes. A) BxGH99 with ManGlucal (7), B) 
BxGH99=E333Q with GlcChex (8) and C) BxGH99 with ManddMan (5). Depicted electron density maps are REFMAC28 maximum 
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likelihood/σA weight 2Fo – Fc syntheses contoured at 1.5 σ (0.57, 0.59 and 0.62 eÅ
–3, respectively. All panels were assembled us=
ing CCP4mg.29 
 
Table 2. X%ray data and structure summary. 
 5 7 8 10 10 + M2 
 (Mandd
Man) 
(Man%
Glucal)  
 (Glc%
Chex) 
(Man%
NOE) 
(Man%
NOE + 
1,2%
α%manno
biose) 
Resolu%
tion  
(outer 
shell) (Å) 
76.77=
1.03 
(1.05=
1.03) 
76.85=
1.07 
(1.09=
1.07) 
39.54=1.2 
(1.22=
1.2) 
76.73=
1.14 
(1.16=
1.14) 
57.21=
1.05 
(1.07=
1.05) 

merge  
(outer) 
0.052 
(0.989) 
0.052 
(1.748) 
0.059 
(0.955) 
0.051 
(1.158) 
0.054 
(1.314) 

cryst/
fre
e 
0.117/0.1
30 
0.124/0.1
41 
0.119/0.1
37 
0.124/0.1
43 
0.115/0.1
33 
Rmsd 
bonds 
(Å) 
0.010 0.011 0.012 0.011 0.013 
Rmsd 
angles (º) 
1.53 1.54 1.59 1.50 1.67 
PDB 
code 
5M17 5M5D 5MEL 5LYR 5M03 
 
have been identified upon which glycals bind as competitive 
inhibitors without exhibiting this mode of reactivity. These are 
N=acetylhexosaminidases that use neighboring group partici=
pation and retaining sialidases, and in both cases these en=
zymes lack a typical carboxylate nucleophile. Retaining N=
acetylhexosaminidases use a 2=acetamido group, which is able 
to catalyze the slow hydration of the enol ether.30 Retaining 
sialidases lack a carboxylate nucleophile capable of protonat=
ing the glycal, and instead use a less acidic tyrosine residue as 
the catalytic nucleophile.31 In the case of sialidases, the corre=
sponding glycal 2,3=didehydro=2=deoxy=N=acetylneuraminic 
acid has been elaborated into the extraordinarily potent inhibi=
tor zanamivir,32 a clinically used antiinfluenza drug. Despite 
its potency, quantitative examination of transition state mimic=
ry by zanamivir reveals it to be a poor transition state mimic.33 
The observation that ManGlucal binds to BxGH99 without a 
chemical reaction despite the retaining mechanism of the en=
zyme provides further evidence in favor of the unique neigh=
boring group participation mechanism proposed for this fami=
ly. 
*		+"			
	((	3	
			
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		
In order to harness the tighter binding of the bacterial en=
zymes with a mannoside in the –2 subsite7 ManddMan (5) was 
synthesized (Scheme 1). NMR titration revealed ManddMan 
to bind to BxGH99 and BtGH99 with KD values of 221 and 53 
M, respectively (Table 1). By comparison, GlcddMan (4) is 
an inhibitor for rat endomannosidase6 with an IC50 value of 3.8 
M for inhibition of cleavage of 14C=labeled GlcMan9GlcNAc, 
only slightly worse than that of GlcDMJ (1) (IC50 = 1.7 M). 
The structure of BxGH99 in complex with ManddMan was 
determined at 1.03 Å resolution. Compound 5 binds in the –
2/–1 subsites of the enzyme in an undistorted 4C1 confor=
mation. This conformation matches that of the ground state of 
the substrate, and while this is consistent with the modest dis=
sociation constant, it is noteworthy that the tight=binding in=
hibitor ManIFG 3 also binds in a 4C1 chair.  
"			4	
	(!$	
						
As ManIFG (3), ManddMan (5) and ManGlucal (7) all 
lack an O2 group, in considering the contribution of shape and 
charge to inhibition, it would appear that the cationic nature of 
ManIFG contributes most significantly to inhibition, in spite 
of its conformational resemblance to the ground state. We 
therefore decided that it would be appropriate to investigate a 
charged inhibitor based on ManIFG that was able to make the 
correct O2 interactions, in particular with E333. Inspired by 
the work of Bols and coworkers on the development of 
noeuromycin, a 2=hydroxy analogue of isofagomine that binds 
2=4,000 times more tightly to various glycosidases,34 we there=
fore synthesized the noeuromycin derivative, ManNOE. This 
inhibitor was synthesized by the regioselective mannosylation 
of the nitrile diol 1635 by trichloroacetimidate 15.36 The sole 
acetate group of the glycoside 17 was cleaved by treatment 
with HCl/MeOH to afford alcohol 18, and the nitrile group 
was reduced using BH3.Me2S, followed by protection as the 
Boc derivative 19. Hydrogenolysis of the benzyl ethers of 19 
using H2/Pd=C, and then cleavage of the Boc group with HCl, 
afforded ManNOE.HCl (9) [as a mixture of α=
hydroxypiperidine and pyranose isomers (not drawn); see SI].  
 
Scheme 2. Synthesis of ManNOE (9). 
 
Isothermal titration calorimetry revealed ManNOE (9) to 
bind to BxGH99 with KD = 13 nM, and to BtGH99 with a KD = 
30 nM, 17= and 5=fold more tightly than ManIFG (3) to the 
respective enzymes, commensurate with improvements seen 
for binding of IFG versus NOE for other enzymes,34,37 and 
demonstrating that better matching of the substrate by rein=
statement of the 2=OH group absent in the latter compound 
provides more effective inhibition (Table 1, Figure S4). 3=D 
structures were solved of a binary complex of BxGH99–
ManNOE, and a ternary complex of BxGH99–ManNOE–α=
1,2=mannobiose at resolutions of 1.14 and 1.05 Å, respectively 
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(Figure 4). The poses of ManNOE in both complexes were 
essentially identical and the more informative ternary com=
plex, with ManNOE in the –2/–1 subsites, and α=1,2=
mannobiose in the +1/+2 subsites will therefore be discussed. 
The NOE heterocycle binds in a 4C1 conformation, similar to 
that seen for ManIFG with the same enzyme. A close contact 
with E333 Oδ…O2 of 2.58 Å is evident, similar to that seen in 
the complex of BxGH99 with GlcDMJ (2.54 Å, PDB 4AD3). 

		
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In order to understand the intrinsic conformational prefer=
ences of the Glucal, 1,2=dideoxymannose (ddMan), Chex, and 
noeuromycin (NOE) inhibitor warheads, so as to help rational=
ize the conformations observed on=enzyme, we calculated 
their conformational free energy landscapes (FELs). FELs 
were computed by ab initio metadynamics (see Methods), and 
the Cremer=Pople puckering coordinates θ and ϕ were used as 
collective variables, yielding a Mercator representation38 for 
each inhibitor FEL (Figure 5). The same procedure has been 
previously used to analyze the conformational preferences of 
related GH inhibitors (mannoimidazole, glucoimidazole, and 
IFG).39,40  
The FELs of both Glucal and Chex (Figures 5A,B) exhibit 
a main energy minimum centered at 4H5. The free energy well 
is quite large and extends through 4E–4H5–E5, with an “arm” 
towards B3,O, indicating substantial conformational freedom 
around 4H5. There is also a local minimum in the southern 
hemisphere, centered at 5H4. However, this is 3 kcal mol
=1 
higher in energy and thus less populated at room temperature. 
Interconversion between the two minima is hindered by an 8 
kcal mol=1 energy barrier. Therefore, both Glucal and Chex 
display only one main accessible conformation at room tem=
perature, 4H5, but can readily adopt the nearby 
4
E confor=
mation predicted for the transition states leading to and from 
the proposed 1,2=anhydrosugar intermediate. These data sug=
gest that Glucal and Chex provide good shape mimicry of the 
transition state or intermediate for the GH99 catalyzed reac=
tion.  
That both Glucal and Chex adopt a 4H5 conformation when 
complexed to BxGH99 (Table 2 and yellow star in Figures 
5A,B) indicates that the conformational preference of the iso=
lated molecules are not significantly perturbed on=enzyme. 
This is also the case for ddMan, for which the FEL (Figure 
5C) is strongly biased towards the 4C1 chair (the local minima 
on the equator are ≈ 8 kcal/mol higher in energy), as observed 
in the X=ray structure on=enzyme. However, the FEL of 
ddMan does not exhibit any stable minimum around 4H5, thus 
it cannot be considered a GH99 transition state shape mimic, 
and should instead be considered a mimic of the substrate con=
formation in the Michaelis complex. 
NOE differs from the other inhibitors considered here as it 
is a basic molecule and was therefore considered as both the 
neutral (Figure  5D) and protonated species (Figure S5). While 
the topographies of the FELs for the two protonation states are 
broadly similar in the gas phase, they differ greatly in relative 
energies, most importantly for the global and local minima, 
such that the most stable state in neutral NOE, a 4C1 chair, 
becomes the 'ring=flipped' 1C4 conformer in protonated NOE. 
In the case of protonated NOE, the two most stable species, 
the 1C4 and 
1
S5 states, are characterized by the presence of 
transannular hydrogen bonds between NH2
+ and O6 or O3, 
respectively. What then is the most appropriate FEL to consid=
er in relation to the enzyme=bound state, which is expected to 
be protonated, but which in a 4C1 conformation lacks a 
transannular hydrogen bond? It is known that in the absence of 
solvation (in the gas phase) flexible molecules in low charge 
states tend to compensate charge effects by forming stabilizing 
intramolecular interactions that do not take place in other envi=
ronments (e.g. in solution). For example, low=charge state 
proteins in the gas phase tend to adopt more compact struc=
tures owing to increased intramolecular interactions.41 On 
balance, we consider the FEL of neutral NOE to be a more 
relevant representation of the enzyme=bound conformations, 
because interactions of the inhibitor with active site residues 
prevent the formation of intramolecular hydrogen bonds that 
dominate the conformations of charged species in the gas=
phase. Accordingly, the FEL for neutral NOE displays a wide 
main minimum situated close to 4C1 (Figure 5D), and is thus 
similar to that of ddMan. The NOE FEL is also reminiscent of 
the one previously computed for the closely related neutral 
IFG inhibitor39 (which differs from NOE by the absence of the 
2=hydroxyl group). Interestingly, the transition state region 
between the north pole and the equator in NOE (4H3/
4
E) is 
shifted by 60º in ϕ in ddMan. This is likely due to a vicinal 
intramolecular hydrogen bond formed between the 2=OH and 
the 3=OH, which stabilizes the 4H3/
4
E conformations in NOE; 
this interaction is not present in ddMan or IFG as they both 
lack a 2=OH. Overall, NOE most closely resembles the con=
formation of the substrate in the Michaelis complex and in its 
protonated state on=enzyme provides mimicry of an oxocarbe=
nium=ion=like transition state; it is therefore best considered a 
'charge'=mimicking inhibitor with no significant shape mimic=
ry of the transition state.  
	!&#%!%	
The proposed GH family 99 neighboring group participa=
tion mechanism, via a 1,2=anhydro sugar, allows prediction of 
a 4C1 → 
4
E
‡
 → 
4
H5 conformational itinerary for the reaction 
coordinate. The FELs for Glucal and Chex suggest that when 
these inhibitor warheads are extended to ManGlucal and 
ManChex, their flattened conformations provide mimicry of 
the 4E transition state and 4H5 intermediate conformations. 
Their non=basic nature provides shape but not charge mimicry 
of the transition state. X=ray structures of these compounds in 
complex with BxGH99 revealed them to bind in a 4H5 confor=
mation, most closely matching the proposed intermediate con=
formation. The modest dissociation constant of ManGlucal, 
and lack of detectable binding for ManChex, suggests that 
shape mimicry of the intermediate or transition state provides 
only weak affinity for the enzyme. On the other hand the FEL 
for the neutral sugar ddMan reveals a preference for a 4C1 con=
formation, and the corresponding complex of ManddMan with 
BxGH99 revealed this compound to bind in the same confor=
mation, albeit with an affinity relative to ManGlucal 8= or 18=
fold worse for Bx or BtGH99 enzymes, respectively. As Man 
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Figure 4. A) X=ray structure of ternary complex of BxGH99 with ManNOE (above) and α=1,2=mannobiose (below). The resi=
due used for NMR titrations, R295, is shown in yellow. 2Fo – Fc map contoured at 1.0 σ (0.42 eÅ
–3). The +1 subsite mannose resi=
due electron density is best modelled by two mannose conformations with 0.6/0.4 occupancy, rotated by about 30° with respect to 
+2 mannose. B) Stereoview of ManNOE in the active site. 2Fo – Fc map contoured at 1.5 σ (0.58 eÅ
–3). Assembled using ccp4mg. 
(A) Glucal       (B) Chex  
 
(C) 1,2=Dideoxy=D=mannose (ddMan)    (D) Noeuromycin 
Figure 5. Conformational free=energy landscapes (FELs, Mercator projection) of isolated Glucal (A), Chex (B), ddMan (C) and 
NOE (D), contoured at 1 kcal mol=1. FELs have been annotated (yellow star) with the inhibitor conformations of ManGlucal 7 (for 
A), GlcChex 8 (for B), ManddMan 5 (for C) and ManNOE 9 (for D) that have been observed on=enzyme in this work. 
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Glucal, ManChex and ManddMan all lack a 2=OH group, the=
se ratios provide an estimate for the contribution of shape=
mimicry of the TS or intermediate to enzyme binding. 
Based on the above analysis, and combined with the previ=
ous discovery that the best inhibitor for GH99 endo=α=
mannanases is ManIFG, which provides charge mimicry, but 
poor transition state shape mimicry, we were inspired to rein=
state the 2=hydroxyl group missing in this compound. Man=
NOE was synthesized and shown to bind to Bx and BtGH99 
with KD values of 30 and 13 nM, the most tightly binding lig=
and for these enzymes yet reported, and a 20=fold enhance=
ment of affinity relative to ManIFG. The NOE FEL reveals a 
distortion of the inhibitor owing to the presence of a hydrogen 
bond between the 2= and 3=OH groups that is lost upon bind=
ing to the enzyme, and we conclude that ManNOE, which 
binds in a 4C1 conformation mimicking the Michaelis complex 
acts primarily to mimic the charge of the transition state.  
	$56$ ($'&	%$!	
X&ray crystallography. Data reduction was performed us=
ing xia242 or XDS suite.43 Dataset HKL index was matched to 
a previous solution using Aimless44,45 software and FreeR set 
was generated from BxGH99–ManddMan data, then used for 
every other dataset. Initial polypeptide chain model was ob=
tained from the same previous solution, refined against 
BxGH99–ManddMan data and used as starting model for other 
structure solutions. Refmac528 with ProSmart was used for 
restrained refinement and Coot46 for real=space refinement. 
During model rebuilding the Fobs–Fcalc difference map was 
examined at 3 σ. Validation was performed using Coot and 
edstats.47 Sugar and pseudopyranose conformations and densi=
ty correlation were validated by Privateer.48,49 
Isothermal titration calorimetry. ManNOE binding to Bt 
and BxGH99 was measured using a MicroCal AutoITC200 
instrument (Malvern Instruments, formerly GE Healthcare) at 
25 °C in 25 mM HEPES pH 7.0, 100 mM NaCl buffer. Protein 
concentration was kept at 5 µM and ligand concentration at 50 
µM. As ManNOE exists as a 5:2 ratio of D=gluco and D=manno 
NOE isomers; the effective ManNOE concentration was ad=
justed accordingly. 
2D NMR titrations. Two=dimensional 1H=15N SOFAST=
HMQC50 spectra were recorded at 298 K for 1 h using 
15N=labeled BtGH99 and BxGH99 on a Bruker AVANCE III 
800 MHz spectrometer with cryoprobe. Upon binding of 
ManGlucal or ManddMan, chemical shift perturbations were 
observed in slow exchange regime. A signal corresponding to 
Nε=Hε of R295 (numbering based on BxGH99), and which is 
close to the enzyme active site, was chosen as binding report=
er. In the case of BxGH99, this signal shifts from δ 7.33, 87.5 
ppm (1H,15N) in the free state to δ 7.41, 87.2 ppm (1H,15N) in 
the bound state. Bound and free protein populations at differ=
ent protein/ligand ratios were calculated from peak intensities. 
NMR measurements were made in 50 mM potassium phos=
phate pH 7.0, 50 mM KCl with 5% D2O added. Protein con=
centration was determined by measuring 280 nm UV absorb=
ance after denaturing the solution in 6 M guanidinium chloride 
(average protein concentration: 58 µM). Ligand concentrations 
were cross verified by integrating the 1H peaks against the 
internal standard TSP=d4 (Sigma=Aldrich). The NMR data 
were processed and integrated using NMRPipe.51 The disso=
ciation constants (KD values) were estimated using in=house 
Matlab 2015b scripts, using the following equation: 


=

 + 

 
where L is the free ligand concentration and ([PL]/PT) is 
the ligand=bound protein fraction. Duplicate experimental 
points were used for error=bar estimation. Errors were propa=
gated using a Monte Carlo algorithm to estimate the uncertain=
ty in the KD values. A distribution of KD values (n = 10000) 
were obtained from datasets randomly varying within the error 
bars, and the standard deviation of was used for the KD error 
estimation. 
Quantum chemical calculations. To obtain the conforma=
tional free energy landscapes of ddMan, Glucal, Chex and 
NOE, quantum mechanical calculations were performed using 
Density Functional Theory=based molecular dynamics (MD), 
according to the Car=Parrinello (CP) method.52 Each molecule 
was enclosed in an isolated cubic box of 12.0 Å × 12.0 Å × 
12.0 Å. A fictitious electron mass of 700 au was used for the 
CP Lagrangian and a time step of 0.12 fs was used in all 
CPMD simulations. The Kohn=Sham orbitals were expanded 
in a plane wave (PW) basis set with a kinetic energy cutoff of 
70 Ry. Ab initio pseudopotentials, generated within the 
Troullier=Martins scheme, were employed.53 The Perdew, 
Burke and Ernzerhoff generalized gradient=corrected approx=
imation (PBE)54 was selected in view of its good performance 
in previous work on isolated sugars,55 glycosidases56 and gly=
cosyltransferases.57  
The metadynamics algorithm,58 provided by the Plumed 2 
plugin,59 was used to explore the conformational free energy 
landscape of the systems, taking as collective variables θ and 
φ of the puckering coordinates of Cremer and Pople,60 in the 
spirit of the pioneering work by Dowd, French and Reilly.61 
Initially, the height of these Gaussian terms was set at 0.6 kcal 
mol=1 and a new Gaussian=like potential was added every 250 
MD steps. Once the whole free energy space was explored, the 
height of the Gaussian terms was reduced to half of its initial 
value (0.3 kcal·mol=1) and a new Gaussian=like potential was 
added every 500 MD steps. The width of the Gaussian terms 
was set to 0.10 Å. The simulations were stopped when energy 
differences among wells remain constant, which was further 
confirmed by a time=independent free energy estimator.62 For 
all molecules, the phase space was fully explored in less than 
60 ps and the simulations were further extended up to 140 ps 
for Chex and Glucal, 160 ps for ddMan and 240 ps for NOE. 
The errors in the principal minima, taken as a standard devia=
tion (SD) from the last 60 ps, are below 0.6 kcal mol=1 (Figure 
S6). 
'%%!'$"	!$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The Supporting Information is available free of charge on the 
ACS Publications website at DOI: 10.1021/xxx. 
 
Experimental procedures, analytical data (1H and 13C NMR, MS) 
for all new compounds. Detailed crystallographic experimental 
and data (PDF) 
'#! 	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!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